亚洲房颤患者标准剂量与低剂量利伐沙班的疗效与安全性
该回顾性人群队列研究利用台湾全民健康保险研究数据库,纳入2014年5月至2015年9月诊断为房颤或房扑并接受利伐沙班治疗的6558例患者,其中2373例用低剂量(10 mg/日),4185例用标准剂量(15或20 mg/日)。与标准剂量相比,低剂量利伐沙班与显著更高的心肌梗死风险相关(亚分布风险比2.26,95%CI 1.13-4.52),而缺血性卒中、系统性栓塞、大出血及非大出血临床相关出血风险相似。
要点
- 亚洲房颤患者中,低剂量利伐沙班(10 mg/日)与标准剂量相比心肌梗死风险显著升高(SHR 2.26)。
- 低剂量与标准剂量利伐沙班在缺血性卒中、系统性栓塞及出血风险方面相似。
- 低剂量利伐沙班在亚洲广泛使用,但需权衡其心肌梗死风险。
核心结论
- 与标准剂量利伐沙班相比,亚洲房颤患者使用低剂量利伐沙班除心肌梗死风险显著升高外,血栓栓塞和出血风险相似。
主要发现
- 低剂量利伐沙班组2373例,标准剂量组4185例;低剂量组心肌梗死风险显著高于标准剂量组(亚分布风险比2.26;95%CI 1.13-4.52)。
- 低剂量与标准剂量利伐沙班在缺血性卒中、系统性栓塞、大出血及非大出血临床相关出血风险方面相似。
临床怎么用
- 亚洲房颤患者选用低剂量利伐沙班(10 mg/日)时,应关注其心肌梗死风险较标准剂量升高,需个体化评估获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose rivaroxaban (10 mg/day) has been widely used in Asia for patients with atrial fibrillation (AF), although there is a lack of evidence regarding its effectiveness. In Asians, it is unclear whether low-dose rivaroxaban is equally effective as that of the standard dose or is associated with less bleeding risk. OBJECTIVES: The aim of this study was to evaluate the effectiveness and safety of standard-dose (15 or 20 mg/day) and low-dose (10 mg/day) rivaroxaban in Asians with AF. METHODS: Using data files from the National Health Insurance Research Database between May 1, 2014, and September 30, 2015, a retrospective population-based cohort study was conducted in patients diagnosed with AF or atrial flutter and treated with low- or standard-dose rivaroxaban. Patients were followed up until the first occurrence of the study outcome or the end of the observation period (December 31, 2015). RESULTS: Among 6,558 eligible patients, a total of 2,373 and 4,185 patients took low- and standard-dose rivaroxaban, respectively. Compared to standard-dose rivaroxaban, low-dose rivaroxaban was associated with a significantly higher risk of myocardial infarction (subdistribution hazard ratio: 2.26; 95% confidence interval: 1.13 to 4.52), with similar risk of ischemic stroke, systemic embolism, major bleeding, and nonmajor clinically relevant bleeding. CONCLUSIONS: Compared to standard-dose rivaroxaban, low-dose rivaroxaban in Asian patients with AF was associated with similar risks of thromboembolism and bleeding except myocardial infarction.
引用
- Lin YC, Chien SC, Hsieh YC, et al. Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation. J Am Coll Cardiol. 2018. PMID: 30049307. doi:10.1016/j.jacc.2018.04.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。